Compare EVTC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | INBX |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 2013 | 2024 |
| Metric | EVTC | INBX |
|---|---|---|
| Price | $30.04 | $70.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $37.00 | ★ $258.33 |
| AVG Volume (30 Days) | ★ 404.7K | 270.4K |
| Earning Date | 11-03-2026 | 11-13-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $453,869,000.00 | $1,300,000.00 |
| Revenue This Year | $17.22 | $53.85 |
| Revenue Next Year | $8.86 | $1,497.70 |
| P/E Ratio | $31.17 | ★ N/A |
| Revenue Growth | 11.48 | ★ 550.00 |
| 52 Week Low | $21.81 | $57.30 |
| 52 Week High | $35.29 | $155.29 |
| Indicator | EVTC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 37.87 |
| Support Level | $27.88 | $66.98 |
| Resistance Level | $31.46 | $97.67 |
| Average True Range (ATR) | 1.51 | 6.84 |
| MACD | -0.46 | -1.05 |
| Stochastic Oscillator | 11.74 | 7.38 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.